ORIGINAL ARTICLE



OPEN ∂ ACCESS

Pediatric cardiac patients with pulmonary hemorrhage supported on ECMO: An ELSO registry study

Pilar Anton-Martin (MD, PhD)^{1,*}, Caroline Young (MD)², Hitesh Sandhu (MD)³, and Shilpa Vellore (MD)⁴

¹ Department of Pediatrics, Division of Anesthesiology and Critical Care Medicine, Children's Hospital of Philadelphia, PA 19130, USA

² Department of Pediatrics, Division of Critical Care, Emory University School of Medicine/Children's Healthcare of Atlanta, Atlanta, GA 30329, USA

³ Department of Pediatrics, Division of Critical Care, University of Tennessee Health Science Center/Le Bonheur Children's Hospital, Memphis, TN 38103, USA

⁴ Department of Pediatrics, Division of Cardiology, University of California San Diego School of Medicine/Rady Children's Hospital, San Diego, CA 92123, USA

Received 24 July 2024, Accepted 25 November 2024

Abstract - Background: Pulmonary Hemorrhage (PH) is a rare but potentially devastating condition and pediatric cardiac patients are at increased risk for. ECMO may be used to safely support these patients, but data is limited. Methods: Observational retrospective cohort study from the ELSO registry database in pediatric cardiac patients from birth to 18 years old with PH supported on ECMO from January 2011 through December 2020. The objectives of the study were to characterize pediatric cardiac patients with PH before ECMO and to describe factors associated with improved survival. Results: A total of 161 cardiac neonates and children with PH supported on ECMO were analyzed. Median age and weight were 40 days (IQR 7.3-452) and 4.06 kg (IQR 3-9.36), respectively. Congenital heart disease accounted for 77% of diagnoses. Survival to hospital discharge was 35.8%. Before ECMO cannulation, most patients were ventilated in conventional modes (79.7%), followed by high-frequency oscillatory (HFOV) ventilation (11%). There was a significantly higher use of HFOV pre-cannulation in survivors compared to non-survivors (24.4% vs 2.8%, p < 0.001). Multivariable logistic regression demonstrated that HFOV before ECMO (OR 28.44, p < 0.001) and the absence of hemorrhagic (OR 3.51, p 0.031) and renal (OR 3.50, p 0.027) complications were independent predictors for survival to hospital discharge. Conclusion: Utilization of HFOV before cannulation to ECMO seems to be associated with improved survival in pediatric cardiac patients with acute pulmonary hemorrhage. A prospective assessment of mechanical ventilation practices before ECMO may improve outcomes in this medically complex population.

Key words: ECMO, High-frequency oscillatory ventilation, Children, Heart disease, Survival.

Introduction

Pulmonary Hemorrhage (PH) is a rare but potentially devastating condition in neonates and children. Massive bleeding may occur secondary to vascular injury (infections, immunemediated processes like vasculitides, drug toxicity), abnormal architecture of the pulmonary vasculature (either congenital or acquired), trauma, etc. [1]. The incidence of massive PH in children is variable depending upon the cause and population reviewed [2]. In their 10-year review of the causes of hemoptysis at a single large institution, Coss Bu et al. reported that the most frequent causes were cystic fibrosis in 65%, congenital heart disease (CHD) in 16%, with the remaining 19% being due to infections, neoplasms, and other causes [2].

Patients with CHD are at increased risk of PH due to multiple factors [3, 4]. However, the true incidence of PH within this subpopulation is particularly difficult to determine due to the paucity of classic PH symptoms [3, 4]. While traditionally hemoptysis, pulmonary infiltrates, and anemia are seen in PH, one or multiple of these signs may be absent or not connected to a unified PH diagnosis in pediatric cardiac patients [3, 5].

Patients with severe PH have been successfully treated with high-frequency oscillatory ventilation (HFOV) [6]. Additionally, extracorporeal membrane oxygenation (ECMO) may be used safely to support pediatric patients with PH, however, outcome data is limited [7–13]. While HFOV may be utilized in

^{*}Corresponding author: pilarantonmartin@gmail.com

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

pediatric heart disease patients with respiratory failure, its use is limited in this population due to the potential for worsening cardiopulmonary interactions [14]. Furthermore, the outcomes of pediatric patients with heart disease who received HFOV as a ventilatory strategy for PH before ECMO cannulation remain unclear. Our study aimed to evaluate predictors of survival to hospital discharge in pediatric cardiac patients with PH requiring ECMO.

Materials and methods

Study setting and design

This study was an observational, retrospective cohort study that utilized the Extracorporeal Life Support Organization (ELSO) registry database. The Institutional Review Board at the University of Tennessee Health Science Center reviewed the study and determined it to be Not Human Subjects Research status.

Study population and data collection

All neonatal and pediatric cardiac patients ≤ 18 years of age with PH supported on ECMO between January 1, 2011, and December 31, 2020, were included in this study. PH was identified using the International Classification of Diseases 9 and 10 codes utilized to identify secondary diagnoses in the ELSO database. ECMO runs with inaccurate data as well as secondary and subsequent runs were excluded. We also excluded those patients who developed PH as an ECMO complication. The data extracted from the ELSO registry database included information regarding demographics, cardiac diagnoses, use of cardiopulmonary bypass (CPB) before cannulation, preextracorporeal life support, ECMO support, complications, and outcomes. Cardiac diagnoses were dichotomized as CHD and heart failure (cardiomyopathy, myocarditis, heart transplant, etc.). Ventilator support was grouped as conventional ventilation, HFOV, and other ventilator modes. The severity of illness indicators available in the dataset at the time of ECMO initiation included pH, oxygenation index (OI), mean blood pressure, arrest before ECMO, nitric oxide use, and renal replacement therapy use. ECMO type was grouped into venovenous and veno-arterial (VA) and ECMO indication was categorized into pulmonary, cardiac, and extracorporeal cardiopulmonary resuscitation (ECPR). Year of ECMO data was also available. However, since most of the patients were clustered over the last 5 years, we did not perform any analysis to evaluate the influence of temporal trends on the outcomes (Fig. 1).

Aims, hypothesis, and outcomes

We aimed to characterize the population of neonatal and pediatric cardiac patients with PH supported on ECMO and to describe factors associated with improved survival. We hypothesized that these patients would benefit from HFOV before cannulation. The primary outcome was survival to hospital discharge. Secondary outcomes were ECMO duration, hospital length of stay (LOS), and mechanical ventilation (MV) duration.

Statistical analysis

Continuous variables were described using medians and interquartile ranges (IQR) while frequencies and proportions were used for categorical variables. Bivariate analyses were conducted using Chi-squared tests and Wilcoxon-Mann-Whitney tests to ascertain the association between covariates and outcomes. Multivariable logistic regression models were used to analyze the effects of potential variables on survival to hospital discharge. Backward selection with an alpha level of removal of 0.05 was utilized. Odds ratios (OR) and 95% confidence intervals were calculated. All *p*-values were 2-sided and p < 0.05 was considered statistically significant. Statistical analyses were performed using SAS (version 9.4, SAS Institute Inc., NC, USA).

Results

Patient population

A total of 161 cardiac neonates and children with PH supported on ECMO between January 2011 and December 2020 were included in this study. The median age and weight of the cohort were 40 days (IQR 7.3–452) and 4.06 kg (IQR 3–9.36). Neonates (<30 days old) accounted for 48.1% of patients. Males were predominant (59%). CHD accounted for 77.2% of diagnoses. The most frequent cardiac diagnoses were transposition of the great arteries (17.3%), hypoplastic left heart syndrome (15.4%), double outlet right ventricle (10%), cardiomyopathy (8.6%), and heart transplant (6.2%). Survival to hospital discharge reached 36% (Table 1).

Support before ECMO, characteristics, and complications

Before ECMO cannulation, most patients were ventilated in conventional modes (79.7%), followed by HFOV (11%) and other ventilator types (6.8%). VA support was the most frequent ECMO mode (94.4%) and cannulation via ECPR occurred in 23.5% of patients. The most frequent ECMO complications in the cohort included the need for renal replacement therapy (44%) and surgical site bleeding (25.3%). Table 1 summarizes the above data.

Patients ventilated on conventional vs HFOV before ECMO

Patients ventilated on HFOV before ECMO had a higher OI (p < 0.001), were more often classified as pulmonary ECMO type (p < 0.001) and exhibited reduced utilization of CPB (p = 0.018) and central cannulation (p = 0.041). Table 2 provides a comparison of pre-ECMO support, characteristics, and complications between patients who received conventional ventilation vs HFOV prior to ECMO cannulation.

Survivors and non-survivors to hospital discharge

No differences were observed in demographic and diagnostic characteristics between both groups. There was a significantly higher use of HFOV pre-cannulation in survivors



Figure 1. Distribution of cardiac patients with pulmonary hemorrhage supported on ECMO over time.

compared to non-survivors (24.4% vs 2.8%, p < 0.001). Non-survivors significantly had more arrests before ECMO than survivors (45.1% vs 29.3%, p 0.044). No differences were observed in ECMO mode and type, cannulation location, and cardiac index provided for support. Survivors had significantly longer LOS and MV duration than non-survivors (43.5 vs 23 days, p < 0.001 and 387 vs 315 h, p 0.01; respectively) likely due to early deaths in the latter. Non-survivors had significantly more cardiovascular, hemorrhagic, mechanical, metabolic, neurologic, respiratory, and renal complications (Table 1).

Factors associated with survival to hospital discharge

Multivariable logistic regression models were used to evaluate factors associated with survival to hospital discharge. After adjusting for confounders, HFOV before ECMO cannulation was an independent predictor for survival to hospital discharge (OR 28.44, p < 0.001). Other predictors of survival were the absence of hemorrhagic (OR 3.51, p 0.031) and renal (OR 3.50, p 0.027) complications during ECMO support. Table 3 summarizes the logistic regression analysis final model after backward selection.

Discussion

This study is the first to date to uniquely characterize predictors of survival to hospital discharge in pediatric cardiac patients with PH requiring ECMO. In our study, HFOV before ECMO cannulation was an independent predictor for improved survival to hospital discharge in this cohort. The absence of renal and hemorrhagic complications were also independent predictors of survival in this population. This finding is supported by prior research that examined the impact of ECMO complications on patient mortality [15, 16].

Pediatric patients with heart disease are at heightened risk for acute PH due to several physiologic factors inherent to their disease process such as increased pulmonary pressures associated with a systemic to pulmonary shunt or elevated downstream pressures (such as left atrial hypertension), formation of arteriovenous malformations, development of veno-occlusive disease or association with bronchopulmonary abnormalities, etc. [3, 4]. Genetic abnormalities (such as Trisomy 21) commonly associated with CHD also independently place these patients at increased risk for PH [17, 18]. Furthermore, while traditionally hemoptysis, pulmonary infiltrates, and anemia are seen in patients with PH, these are often non-existent or attributed to other causes in infants and children with CHD complicating an early PH diagnosis [3, 5].

HFOV offers the theoretical benefit of minimizing ventilator-associated lung injury but data supporting positive outcomes have varied in previous research [19]. When employed in patients with acute PH, HFOV offers the advantage of high mean airway pressures that could help tamponade ongoing bleeding [14]. HFOV however is traditionally used with hesitancy in pediatric patients with heart disease due to the potential effects of increased intrathoracic pressure in reducing pulmonary venous return and/or increasing right ventricular afterload, thereby decreasing overall cardiac output [14]. However, some studies did not demonstrate hemodynamic deterioration using HFOV in non-operated and postoperative pediatric heart disease patients [14, 20]. Our study indicates that the use of HFOV in pediatric patients with heart disease and acute PH is a feasible option that may have contributed to improvement in survival. This may be attributable to the control of alveolar hemorrhage and subsequent improvement in lung compliance and gas exchange leading to better outcomes. Patients in the HFOV group were likely predisposed to respiratory conditions with severe oxygenation deficits. Variations in disease characteristics and comorbidities between ventilation groups, not captured by the ELSO registry, may have also influenced differences in survival. The use of ECMO for severe respiratory failure due to PH was historically discouraged given the need for systemic anticoagulation. However, several pediatric case studies have demonstrated that ECMO is feasible to manage life-threatening PH refractory to conventional therapy and allows time for diagnosis-directed therapies [7-13]. The observed survival benefit identified in this study and the paucity of prior research examining this association proffers an excellent opportunity to prospectively evaluate ventilatory strategies in pediatric cardiac patients with PH before ECMO cannulation.

Tuble It Characteristics of survivors and non survivors to nospital alsonaige.	Table 1.	Characteristics	of survivors	and non-survivors	to hospital discharge.
---	----------	-----------------	--------------	-------------------	------------------------

Characteristics	All cohort $(n = 161)$	Survivors to hospital	Non-survivors to	<i>p</i> -value
		discharge ($n = 58, 36\%$)	hospital discharge $(n = 103, 64\%)$	1
A ()8		Demographic data		0.000
Age (years) ^a	0.11 (0.02, 1.24)	0.1 (0, 0.9)	0.1 (0, 1.5)	0.238
Neonate (<30 days)	78 (48.1)	28 (48.3)	50 (48.5)	0.975
Pediatric	83 (51.5)	30 (51.7)	53 (51.5)	
Weight (kg) ^a	4.06 (3, 9.36)	4.2 (3.3, 8.6)	4 (3, 10.4)	0.805
Height (cm) ^a	62.5 (49, 95.3)	59.5 (51, 73)	65.8 (49, 107.4)	0.491
$BSA (m^2)^a$	0.31 (0.21, 0.62)	0.3 (0.2, 0.5)	0.4 (0.2, 0.7)	0.661
Gender ^b				0.232
Female	63 (39.6)	19 (32.8)	44 (44)	
Male	95 (59)	39 (67.2)	56 (56)	
Race				0.854
Caucasian	91 (56.5)	32 (55.2)	59 (57.3)	
African-American	27 (16.7)	11 (19)	16 (15.5)	
Other b	43 (26.8)	15 (25.8)	28 (27.2)	0.055
Diagnostic group	125 (77.2)	40 (94 5)		0.055
CHD Haart failteau	125(77.2)	49 (84.5)	/6 (/3.8)	
Heart failure	36 (22.3)	9 (15.5)	27(20.2)	0 6 9 1
Heart transplant	10 (6.2)	5 (5.2) Dra ECMO data and surrant	7 (0.8)	0.081
Vantilaton gunnant ^b		Pre-ECMO data and support		-0.001
Conventional	04 (70 7)	22 (72 2)	60 (82.2)	<0.001
	94(79.7)	35(73.3) 11(24.4)	2(28)	
Other	11 (6.8)	11(24.4) 1(2.2)	2(2.8) 10(120)	
Pre ECMO arrest ^b	63 (30)	1(2.2) 17(203)	10(13.9) 46(451)	0.044
Ovvgenation index ^a	35(14,55)	39(23,57)	325(10551)	0.154
Mean BP (mmHg) ^a	41 5 (32 53)	42(32,57)	41(315(525))	0.918
FiO2 need $(\%)^a$	100(87,100)	100(91,100)	100(82, 100)	0.517
nH ^a	72(705,732)	72(71,73)	72(7,73)	0.485
CPB ^b	63 (39)	27 (46.6)	36 (35)	0.232
VAD ^b	10 (6.2)	4 (6.9)	6 (5.8)	0.768
RRT ^b	2(1.2)	0 (0)	2(1.9)	0.540
Nitric oxide ^b	56 (34.7)	24 (41.4)	32 (31.1)	0.325
		ECMO data		
ECMO mode ^b				0.843
Veno-arterial	153 (94.4)	55 (94.8)	97 (94.2)	
Veno-venous	7 (4.3)	2 (3.4)	5 (4.9)	
Unknown	2 (1.2)	1 (1.7)	1 (1)	
ECMO type ^b				0.269
Cardiac	114 (70.4)	42 (72.4)	72 (69.9)	
Pulmonary	10 (6.2)	5 (8.6)	5 (4.9)	
ECPR	38 (23.5)	11 (19)	26 (25.2)	
Cannula location	0- (6 0, 6)			0.396
Central	97 (60.6)	37 (63.8)	60 (59.4)	
Peripheral	63 (39.4)	21 (36.2)	41 (40.6)	0.050
Cardiac index."	1.97 (1.57, 2.47)	2 (1.5, 2.4)	1.9 (1.6, 2.5)	0.853
	120 5 (72, 218)	Outcomes and complications	127 (52, 212)	0.000
ECMO duration (h) ^a	130.5(73, 218)	105.5 (81, 161)	137(53, 312)	0.222
LUS (days) ⁻	29(16.5, 53.5)	43.5 (29, 109)	23(11, 36) 215(125, 580)	<0.001
MV duration (II)	336 (172, 634)	387 (240, 721)	315 (125, 580)	0.01
Complication type	71 (42.8)	15 (25.0)	56 (54 4)	~0.001
Hemorrhagic	71 (45.8) 78 (48.1)	13(23.9) 18(31)	50 (54.4) 60 (58.3)	
Infectious	12 (74)	10(31) 1(17)	11 (10.7)	0.001
Limh	$\frac{12}{4}$ (2.5)	0(0)	$\Delta (3.0)$	0.127
Mechanical		11 (19)	$\frac{1}{42} (40.8)$	0.322
Metabolic	41 (25 3)	8 (13.8)	33 (32)	0.017
Neurologic	35 (21.6)	6 (10.3)	29 (28.2)	0.012
Respiratory	44 (27.2)	6 (10.3)	38 (36.9)	< 0.001
Renal	73 (45.1)	19 (32.8)	54 (52.4)	0.023

^a Medians (IQR). ^b Frequencies (%).

BP: blood pressure, BSA: body surface area, CHD: congenital heart disease, CPB: cardiopulmonary bypass, ECMO: extracorporeal membrane oxygenation, ECPR: extracorporeal cardiopulmonary resuscitation, FiO2: fraction of inspired oxygen, HFOV: high-frequency oscillatory ventilation, h: hours, LOS: length of stay, MV: mechanical ventilation, RRT: renal replacement therapy, VAD: ventricular assist device. Heart failure includes cardiomyopathy, myocarditis, and heart transplant.

P. Anton-Martin et al.: J Extra Corpor Technol 2025, 57, 2-8

1 abic 2. Characteristics of patients that received conventional ventilation vs in Ov phot to Letvic calification.	Table 2.	Characteristics of	patients that 1	received	conventional	ventilation vs	HFOV	prior to ECMO cannulation.
---	----------	--------------------	-----------------	----------	--------------	----------------	------	----------------------------

Demographic data Age (yeary) ^k 0.12 (0.02, 1.02) 0.5 (0.01, 1.98) 0.942 Age (yeary) ^k 0.12 (0.02, 1.02) 0.5 (0.01, 1.98) 0.942 Neonnet (5.30 days) 42 (44.5) 6 (46) 0.920 Neonter (5.30 days) 42 (3.5) 5 (6.1, 12) 0.432 Height (rap) ^k 42 (3.5) 5 (6.1, 12) 0.432 BSA (m ²) 0.32 (0.22, 0.62) 0.28 (0.20, 0.47) 0.416 Gende ^k 9 (69.3) 0.368 7 (7.5) 9 (69.3) Race ^k 20 (31) 6 (47) 0.501 Other 29 (31) 6 (47) 0.501 Diagnostic group ^k 21 (22.4) 4 (31) 0.757 Other 23 (35) 0 (00) N/A Pre ECMO arrest ^k 33 (35) 4 (31) 0.0757 Oxagention index ^k 27 (12, 48) 43 (45, 88) 0.000 Pre ECMO arrest ^k 33 (35) 6 (22, 858) 0.002 Pre ECMO arrest ^k 7 (9, 10, 7, 31) 7 (7.6) 0.001 N/A </th <th>Characteristics</th> <th>Conventional $(n = 94)$</th> <th>HFOV $(n = 13)$</th> <th><i>p</i>-value</th>	Characteristics	Conventional $(n = 94)$	HFOV $(n = 13)$	<i>p</i> -value
Age (cars)* 0.12 (0.02, 1.02)*** 0.5 (0.01, 1.98) 0.942 Neonate (5.30 days) 42 (44.5) 6 (46) 0.920 Neonate (5.30 days) 42 (44.5) 5 (6 (3, 12) 0.432 Pediatic 42 (3, 9) 5 5 (3, 12) 0.432 Heipht (cm)* 64.5 (50, 98) 5.87 (48, 77) 0.337 BSA (m3*)* 0.32 (0.22, 0.62) 0.28 (0.20, 0.47) 0.416 Gender* 0.349 0.349 0.349 Kare* 0.349 0.349 0.349 Caucasian 49 (52) 4 (31) 0.416 Dignostic group* 0.01 0.01 N/A CHD 73 (77.6) 9 (69) 0.01 Heart falue 21 (22.4) 4 (31) 0.757 Oxgenation index* 27 (12.48) 43 (45.88) 0.000 Mae BY (nmHg)* 43 (35, 53) 6 (28, 88) 0.002 Dignostic group* 0.00 N/A 0.00 N/A CRECMO arrest* 33 (35) 4 (31) 0.757 0.757		Demographic dat	a	
Age group ⁵ 0.920 Nonane (250 days) 42 (44.5) 6 (46) Pediatric 52 (55.5) 7 (54) Weight (kg) ⁶ 4.2 (3, 9) 5.6 (3, 12) 0.432 BSA (m ⁷) 0.32 (0.22, 0.62) 0.28 (0.20, 0.47) 0.416 Gender ⁴ 0.0425 4 (30.7) Mate Male 51 (57.5) 9 (09.3) 7.413 Rac ⁶ 0.308 7.433 7.413 Caucasian 40 (42.5) 4 (31) 7.413 African-American 16 (17) 3 (22) 0.01 Other 29 (31) 6 (47) 0.00 Diagnostic group ⁶ 0.00 N/A Heart frainsplant ⁶ 21 (22.4) 4 (31) 0.757 Other 31 (35) 6 2 (28, 58) 0.000 Wein B' (mmftg) ⁴ 43 (35, 55) 6 2 (28, 58) 0.001 Pe ECMO arrest ¹ 7.19 (7.10, 7.31) 7.347 0.819 CHU 9 (9.5) 0 (0) N/A Pipe 39 (41.4)	Age (years) ^a	0.12 (0.02, 1.02)	0.5 (0.01, 1.98)	0.942
Nemate (ζ_{30}^{20} days) 42 (44.5) 6 (46) Pediatic 52 (55.5) 7 (54) Weight (kg)" 4.2 (3, 9) 5.6 (3, 12) 0.327 BA (m ³)" 0.32 (0.22, 0.62) 0.28 (0.20, 0.47) 0.416 Gender" 0.336 0.368 Female 40 (42.5) 4 (30.7) 0.369 Male 51 (57.5) 9 (69.3) 0.349 Cuccarian 40 (52) 4 (31) 0.501 Other 29 (31) 6 (47) 0.501 Dilagnostic group" 0.00 N/A Ch1D 73 (77.6) 9 (69) 0.00 Heart failure 12 (22.4) 4 (31) 0.757 Oxegenation index" 27 (12, 48) 43 (45.88) -0.000 Oxegenation index" 27 (12, 48) 43 (45.88) -0.001 Mean BP (mmHg)" 43 (33.53) 62 (28.58) 0.002 Oxegenation index" 27 (12, 48) 43 (45.88) -0.001 Male 9 (9.5) 0 (0) N/A 0.018 <td>Age group^b</td> <td></td> <td></td> <td>0.920</td>	Age group ^b			0.920
Pediatric 52 (55.5) 7 (54) Weight (kg)* 4.2 (3.9) 5.6 (3.12) 0.432 Height (km)* 0.32 (0.22, 0.62) 0.28 (0.20, 0.47) 0.446 Gender* 0.32 (0.22, 0.62) 0.28 (0.20, 0.47) 0.446 Gender* 0.32 (0.22, 0.62) 0.28 (0.20, 0.47) 0.349 Male 51 (57.5) 9 (69.3) 0.349 Caucasian 49 (52) 4 (31) 4 African-American 16 (17) 3 (22) 0.501 Charcasin 29 (31) 6 (47) 0.501 Chart 29 (31) 6 (47) 0.501 Heart transplant* 8 (8.5) 0 (0) N/A Pre-ECMO arrest* 0.303 62 (28, 58) 0.9002 Froe mether* 33 (35 62 (28, 58) 0.9002 Froe arcet (%) 100 (75, 100) 1000 (100, 100) 0.902 Froe arcet (%) 100 (75, 100) 1000 (100, 100) 0.802 Char arcet (%) 100 (75, 100) 100 (100, 100) 0.802 Che	Neonate (\leq 30 days)	42 (44.5)	6 (46)	
Weight (kg)" 4.2 (3, 9) 5.6 (3, 12) 0.432 BAA (m ³)" 0.32 (0.22, 0.62) 0.28 (0.20, 0.47) 0.416 Gender" 0.36 (0.22, 0.62) 0.28 (0.20, 0.47) 0.416 Male 51 (57,5) 9 (69,3) 0.36 Rec" 0.349 0.349 Caucasian 49 (52) 4 (31) 0.417 Caucasian 16 (17) 3 (22) 0.01 NAica Other 29 (31) 6 (47) 0.501 0.501 Diagnostic group" 0.501 0.601 NA NA Heart failure 21 (22, 4) 4 (31) 0.757 NA Heart failure 21 (22, 4) 4 (31) 0.757 0.9902 0.902	Pediatric	52 (55.5)	7 (54)	
Height (em)* $645.(60, 98)$ $58.7 (48, 77)$ 0.327 BSA (m^3)* $0.322 (0.22, 0.62)$ $0.28 (0.20, 0.47)$ 0.416 Gender* 0.0425 $4.30.7$ 0.368 Female 0.0425 $4.30.7$ 0.349 Male51 (57.5) $9 (69.3)$ 0.349 Cucasian $40 (42.5)$ 4.31 0.349 Cucasian $16 (17)$ $3.(22)$ 0.647 Other $29.(31)$ $6.(47)$ 0.501 Heart transplant* $21.(22.4)$ $4.(31)$ 0.757 Reart transplant* $8.(8.5)$ $0.(0)$ N/A Pre ECMO arrest* $33.(35)$ $62.(28.58)$ 0.902 FiO2 need (%)* $100.(75.100)$ $100.(100.100)$ 0.092 FiO2 need (%)* $100.(75.100)$ $100.(100.100)$ 0.092 FiO2 need (%)* $1.(1)$ 0.00 N/A RT* $1.31.3$ $3.(23.2)$ 0.974 Veno-arterial $7.(92.5)$ $1.97.(15.2.0)$ 0.482 CMO mode* $0.92.3$ $3.(23.2)$ 0.974 Veno-arterial $7.(90.6)$ $4.(31)$ 0.482 Cucasia $7.(55.3)$ $5.(38.4)$ 0.974 Veno-arterial $7.(90.6)$ $4.(31)$ 0.482 Cucasia $7.(90.6)$ $4.($	Weight (kg) ^a	4.2 (3, 9)	5.6 (3, 12)	0.432
BSA (m ²) ^a 0.32 (0.22, 0.62) 0.28 (0.20, 0.47) 0.416 Female 40 (42.5) 4 (30.7) 0.368 Female 40 (42.5) 9 (69.3) 0.349 Race ^b 0.349 0.368 0.368 Caucasian 49 (52) 4 (31) 0.369 Cher American 16 (17) 3 (22) 0.00 N/A Other 29 (31) 6 (47) 0.501 0.00 N/A Heart failure 21 (22.4) 4 (31) 0.507 0.00 N/A Heart failure 21 (22.4) 4 (31) 0.757 0.000 N/A Coxgenation index ⁴ 27 (12, 48) 4 (34) 0.501 0.000 N/A Fee ECMO arrest ^b 33 (35) 6 2 (28, 58) 0.000 N/A Race 100 (75, 100) 100 (100, 100) 0.002 pH VaD ^a 9 (9.5) 0 (00) N/A N/A KPE ECMO ande ^a 0.753 1 (7.6) 0.862 0.862 V	Height (cm) ^a	64.5 (50, 98)	58.7 (48, 77)	0.327
Gender ^b 0,368 Female 40 (42.5) 4 (30.7) Male 51 (57.5) 9 (69.3) Race ^b 0,349 Caucasian 49 (52) 4 (31) African-American 16 (17) 3 (22) Other 29 (31) 6 (47) Diagnostic group ^b 0,00 N/A Ferrat failure 21 (22.4) 4 (31) Heart transplant ^b 8 (8.5) 0 (0) N/A Pre-ECMO data and support 0,757 0xygenation index" 27 (12, 48) 43 (45, 88) -0,001 Mean BP (mmHg)' 43 (33, 53) 62 (28, 88) 0,902 0,902 DFB' 39 (41.4) 1 (7.6) 0,018 0,00 N/A KTP' 1.0 0.000 N/A 0,00 N/A VAD ^b 9 (9.5.) 0.00 N/A 0,018 VAD ^b 9 (9.5.) 0.00 N/A 0,018 VAD ^b 9 (9.5.) 1 (7.6) 0.018 0,018 VAD ^b	BSA $(m^2)^a$	0.32 (0.22, 0.62)	0.28 (0.20, 0.47)	0.416
Fenale 40 (42.5) 4 (30) Male 51 (57.5) 9 (69.3) Race ^b 0.349 Cancasian 49 (52) 4 (31) African-American 16 (17) 3 (22) Other 29 (31) 6 (47) Diagnostic group ^b 0.501 CHD 73 (77.6) 9 (69,) Heart failure 21 (22.4) 4 (31) 0.757 CHD 73 (75.6) 4 (31) 0.757 Oxgenation index* 27 (12, 48) 43 (35, 53) 60 (00) 0.902 FIO2 need (%)* 100 (75, 100) 100 (100, 100) 0.902 0.902 FIO2 need (%)* 9 (9.5) 0 (00) N/A VPb* 9 (9.5) 0 (00) N/A RT* 1 (1) 0 (00) N/A Veno-arterial 87 (92.5) 1 (7.6) 0.901 Veno-venous 7 (7.5) 1 (7.6) 0.901 CEMO type* Coutcomes and complications 0.901 Centrai 7 (60.6) <t< td=""><td>Gender^b</td><td></td><td></td><td>0.368</td></t<>	Gender ^b			0.368
Male 51 (57.5) 9 (69.3) Race ² 0.349 Caucasian 49 (52) 4 (31) African-American 16 (17) 3 (22) Other 29 (31) 6 (47) Diagnostic group ^b 0.501 0.501 CHD 73 (77.6) 9 (69) Heart transplant ^b 8 (8.5) 0.00 N/A Pre-ECMO data and support 7 7.75) 9 (69) Heart transplant ^b 8 (8.5) 0.00 N/A Pre-ECMO data and support 7 7.75) 0.001 0.001 Pre-ECMO data and support 7 7.75 0.902	Female	40 (42.5)	4 (30.7)	
Race ^b 0.349 Caucasian 49 (52) 4 (31) African-American 16 (17) 3 (22) Other 29 (31) 6 (47) Diagnostic group ^b 0.501 0.501 CHD 73 (77.6) 9 (69) Heart failure 21 (22.4) 4 (31) Heart failure 21 (22.4) 4 (31) Pre-FCMO data and support 7 7.5 Pre-ECMO arrest ^a 33 (35) 4 (31) 0.757 Oxygenation index ^a 27 (12, 48) 43 (45, 88) -0.001 Wena BP (mmHig) ^a 43 (35, 53) 6 (28, 58) 0.002 FIO2 need (%) ^a 100 (75, 100) 100 (100, 100) 0.092 PI ⁺ 7.19 (7.10, 7.31) 7.34 (7.05, 7.34) 0.819 CPB ^b 39 (41.4) 1 (7.6) 0.018 VAD ^b 9 (9.5) 0 (0) N/A Nitric oxide ^b 1 (1) 0 (0) N/A Veno-arterial 87 (92.5) 1 2 (92.3) Cetto Cardiac	Male	51 (57.5)	9 (69.3)	
Caucasian 49 (52) 4 (31) African-American 16 (17) 3 (22) Other 29 (31) 6 (47) Diagnostic group ^b 0 (0) N/A CHD 73 (77.6) 9 (69) Heart failure 21 (22.4) 4 (31) Heart transplant ^b 8 (8.5) 0 (0) N/A D'sygenation index ^a 27 (12, 48) 43 (45, 88) -0.001 Mean BP (numHg) ^a 43 (33, 53) 62 (28, 58) 0.902 D'BO need (%) ^a 100 (75, 100) 100 (100, 100) 0.002 pH ^a 7.19 (7.10, 7.31) 7.34 (7.05, 7.34) 0.819 CPB ^b 39 (9.5) 0 (0) N/A NRT ^b 9 (9.5) 0 (0) N/A RRT ^b 1 (1) 0 (0) N/A RRT ^b 1 (1) 0 (0) N/A Veno-venous 7 (7.5) 1 (7.6) 0.001 Cardia 76 (60.8) 5 (38.4) 100 Pulmonary 5 (5.3) 5 (38.4) 100 <td>Race^b</td> <td></td> <td></td> <td>0.349</td>	Race ^b			0.349
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Caucasian	49 (52)	4 (31)	
Other 29 (31) 6 (47) Diagnostic group' 0.501 CHD 73 (77.6) 9 (69) Heart failure 21 (22.4) 4 (31) Heart transplant' 8 (8.5) 0 (0) NA Pre-ECMO data and support 71 (72.48) 43 (45.88) <0.001	African-American	16 (17)	3 (22)	
Diagnostic group? 0.501 CHD 73 (77.6) 9 (69) Heart failure 21 (22.4) 4 (31) Heart transplant* 8 (8.5) 0 (0) NA Pre ECMO arrest* 33 (35) 4 (31) 0.757 Oxygenation index* 27 (12, 48) 43 (45, 88) <0.002	Other	29 (31)	6 (47)	
$\begin{array}{ccc} \dot{ChD} & T3 (7.6) & 9 (69) \\ Heart failure & 21 (22.4) & 4 (31) \\ Heart transplantb & 8 (8.5) & 0 (0) & N/A \\ \hline Pre ECMO arrestb & 33 (35) & 4 (31) & 0.757 \\ Oxygenation indexa & 27 (12, 48) & 43 (45, 88) & <0.001 \\ Mean BP (mmHg)b & 43 (33, 53) & 62 (28, 58) & 0.902 \\ FlO2 need (%)a & 100 (75, 100) & 100 (100, 100) & 0.092 \\ pHa & 7.19 (7.10, 7.31) & 7.34 (7.05, 7.34) & 0.819 \\ VDb & 9 (9.5) & 0 (0) & N/A \\ RRTb & 1 (1) & 0 (0) & N/A \\ RRTb & 1 (1) & 0 (0) & N/A \\ RRTb & 1 (1) & 0 (0) & N/A \\ RRTb & 1 (1) & 0 (0) & N/A \\ RRTb & 1 (1) & 0 (0) & N/A \\ RRTb & 1 (1) & 0 (0) & N/A \\ Cardica & 76 (80.8) & 5 (38.4) & \\ ECMO modeb & & & & & & & \\ CCMO (typeb & & & & & & & & & \\ Cardiac & 76 (80.8) & 5 (38.4) & & & & & & & & \\ ECMO (typeb & & & & & & & & & & & & & \\ Cardiac & 76 (80.8) & 5 (38.4) & & & & & & & & & & & \\ ECMO (typeb & & & & & & & & & & & & & & & \\ Cardiac & 76 (80.8) & 5 (38.4) & & & & & & & & & & & & \\ Cardiac indexa & 1.97 (16, 2.5) & 1.97 (15, 2.0) & 0.482 & & & & & & & & \\ Coutomes and complications & & & & & & & & & & & & & \\ Cardiac indexa & 1.97 (16, 2.5) & 1.97 (15, 2.0) & 0.482 & & & & & & & & & & \\ Cardiac indexa & 1.97 (16, 2.5) & 1.97 (15, 2.0) & 0.482 & & & & & & & & & \\ Cardiac indexa & 1.97 (16, 2.5) & 1.97 (15, 2.0) & 0.482 & & & & & & & & & \\ Cardiox indexa & 0.974 & & & & & & & & & & & & & & & & & & &$	Diagnostic group ^b			0.501
Heart failure 21 (22.4) 4 (3) Heart transplant ^b 8 (8.5) 0 (0) N/A Pre-ECMO data and support V V V Oxygenation index ^a 23 (35) 4 (31) 0.757 Oxygenation index ^a 27 (12, 48) 43 (45, 88) c0.001 Mean BP (numHg) ^a 43 (33, 53) 62 (28, 58) 0.902 FiO2 need (%) ^a 100 (75, 100) 100 (100, 100) 0.092 DPb 39 (41.4) 1 (7.6) 0.819 CPB ^b 39 (41.4) 1 (7.6) 0.013 KD ^b 9 (9.5) 0 (0) N/A RT ^b 1 (1) 0 (0) N/A Nitric oxide ^b 41 (4.6) 6 (46) 0.820 Veno-arterial 87 (92.5) 12 (92.3) 0 Veno-arterial 87 (92.5) 1 (7.6) 0.011 Cardiac 76 (80.8) 5 (38.4) 0 Decipe 0 0.01 0.041 Cardiac index ^a 1.97 (1.6, 2.5) 1.97 (1.5	CHD	73 (77.6)	9 (69)	
Heart transplant ^b 8 (8.5) 0 (0) N/A Pre ECMO arrest ^b 37 (25) 4 (31) 0.757 Oxygenation index ^a 27 (12, 48) 43 (45, 88) -0.001 Mean BP (mmHg) ^a 43 (33, 53) 62 (28, 58) 0.902 FiO2 need (%) ^a 100 (75, 100) 100 (100, 100) 0.092 pH 7.19 (7.10, 7.31) 7.34 (7.05, 7.34) 0.819 VB ^b 39 (41.4) 1 (7.6) 0.018 VAD ^b 9 (9.5) 0 (0) N/A Nitric oxide ^b 41 (43.6) 6 (46) 0.862 ECMO mode ^b 0.974 Veno-venous 7 (7.5) 1 (7.6) Veno-venous 7 (7.5) 1 (7.6) 0.001 Cardiac 76 (80.8) 5 (38.4) 9 Pulmonary 5 (5.3) 5 (38.4) 0.012 Cardiac index ^a 107 (1.6, 2.5) 1.97 (1.5, 2.0) 0.42 Cerral 137 (39.4) 9 (69) 0.303 Cardiac index ^a 1.97 (1.6, 2.5) 1.97 (1.5, 2.0) 0.43	Heart failure	21 (22.4)	4 (31)	
Pre-ECMO data and support Pre ECMO arrest ¹ 33 (35) 4 (31) 0.757 Oxygenation index ^a 27 (12, 48) 43 (45, 58) -0.001 Mean BP (mmHg) ^a 43 (33, 53) 62 (28, 58) 0.902 FiO2 need (%) ^a 100 (75, 100) 100 (100, 100) 0.092 pH ⁻ 7.19 (7.10, 7.31) 7.34 (7.05, 7.34) 0.819 CPB ^b 39 (41.4) 1 (7.6) 0.018 VAD ^b 9 (9.5) 0 (0) NAA NItric oxide ^b 41 (43.6) 6 (46) 0.822 Veno-venous 7 (7.5) 1 (7.6) 0.074 Veno-venous 7 (7.5) 1 (7.6) 0.041 Cardiac 76 (80.8) 5 (38.4) - Pulmonary 5 (5.3) 5 (38.4) - Purpheral 37 (39.4) 9 (69) - Cardiac index ^a 1.97 (1.6, 2.5) 1.97 (1.5, 2.0) 0.482 Outcromes and complications - - - Cardia '1.97 (1.6, 2.5) 1.97 (1.5, 2.0)	Heart transplant ^b	8 (8.5)	0 (0)	N/A
Pre ECMO arrest ^h 33 (35) 4 (31) 0,757 Oxygenation index ^a 27 (12,48) 43 (45,88) <0.001 Mean BP (mmHg) ^a 43 (33,53) 62 (28,58) 0.902 FIO2 need (%) ^a 100 (75,100) 100 (100,100) 0.092 pH ^a 7.19 (7.10,7.31) 7.34 (7.05,7.34) 0.819 ORP ^b 39 (41.4) 1 (7.6) 0.018 VAD ^b 9 (9.5) 0 (0) NA RRT ^b 1 (1) 0 (0) NA Nitric oxide ^b ECMO data 0.974 Condet ^b 0.974 Veno-arterial 87 (92.5) 12 (92.3) 0 Veno-arterial 87 (92.5) 12 (92.3) 0 Cardiac 7 (5.5) 12 (92.3) 0 Cardiac 7 (5.5) 12 (92.3) 0 Condata 0.001 CArdiac 7 (7.5) 12 (92.3) 0.012 Cardiac 7 (6.6,0) 4 (31) 0.418 Pulmonary 5 (5.3) 5 (1	•	Pre-ECMO data and s	upport	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Pre ECMO arrest ^b	33 (35)	4 (31)	0.757
Mean BP (mmHg) ^a 43 (33, 53) 62 (28, 58) 0.902 FIO2 need (%) ^a 100 (75, 100) 100 (100, 100) 0.092 pH ^a 7.19 (7.10, 7.31) 7.34 (7.05, 7.34) 0.819 CPB ^b 39 (41.4) 1 (7.6) 0.018 VAD ^b 9 (9.5) 0 (0) NA Nitric oxide ^b 41 (43.6) 6 (46) 0.862 ECMO mode ^b 0.974 Veno-venous 7 (7.5) 1 (7.6) 0.974 Veno-venous 7 (7.5) 1 (7.6) 0.974 Candiac 76 (80.8) 5 (38.4) 0.974 Pulmonary 5 (5.3) 5 (38.4) 0.001 NA ECPR 13 (13.9) 3 (23.2) 0.041 0.041 Central 57 (60.6) 4 (31) 0.482 0.042 Deripheral 37 (39.4) 9 (69) 0.432 0.432 Cardiac index ^a 1.97 (1.6, 2.5) 1.97 (1.5, 2.0) 0.482 0.042 Cardiac index ^a 1.97 (2.5, 2.5) 1.9	Oxygenation index ^a	27 (12, 48)	43 (45, 88)	< 0.001
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Mean BP (mmHg) ^a	43 (33, 53)	62 (28, 58)	0.902
pH 7.19 (7.10, 7.31) 7.34 (7.05, 7.34) 0.819 CPB ^b 39 (41.4) 1 (7.6) 0.018 RRT ^b 9 (9.5) 0 (0) NA RRT ^b 1 (1) 0 (0) NA Nitric oxide ^b 41 (43.6) 6 (46) 0.862 ECMO mode ^b 0.974 Veno-arterial 87 (92.5) 12 (92.3) 0.974 Veno-Venous 7 (7.5) 1 (7.6) 0.001 Cardiac 76 (80.8) 5 (38.4) 0.974 Pulmonary 5 (5.3) 5 (38.4) 0.001 Cardiac index ^a 76 (80.8) 5 (38.4) 0.001 Central 76 (60.6) 4 (31) 0.482 Central 57 (60.6) 4 (31) 0.482 Outcomes and complications 0.021 0.482 0.303 LOS (days) ^a 31 (21, 56) 38 (22, 53) 0.303 LOS (days) ^a 31 (21, 742) 364 (201, 566) 0.660 Complication (h) ^a 378 (216, 742) 364 (201, 566)	FiO2 need $(\%)^a$	100 (75, 100)	100 (100, 100)	0.092
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	pH ^a	7.19 (7.10, 7.31)	7.34 (7.05, 7.34)	0.819
VAD ^b 9 (9.5) 0 (0) NA RRT ^b 1 (1) 0 (0) NA Nitric oxide ^b 41 (43.6) 6 (46) 0.862 ECMO data ECMO mode ^b 0.974 Veno-arterial 87 (92.5) 12 (92.3) 0.974 Veno-venous 7 (7.5) 1 (7.6) $<$ Cardiac 76 (80.8) 5 (38.4) $<$ Pulmonary 5 (5.3) 5 (38.4) $<$ $<$ Cerral 77 (60.6) 4 (31) $<$ $<$ Peripheral 37 (39.4) 9 (69) $<$ $<$ $<$ Cardiac index ^a 1.97 (1.6, 2.5) 1.97 (1.5, 2.0) $<$ $<$ Autraitor (h) ^a 137 (90, 282) 130 (72, 163) $<$ $<$ Cardiac index ^a 1.97 (1.6, 2.5) 3.8 (22, 53) $<$ $<$ Cardiac index ^a 1.97 (1.6, 2.5) 3.8 (22, 53) $<$ $<$ Cardiac index ^a 1.97 (1.6, 2.5) $<$ $<$ $<$ Cardiac	CPB ^b	39 (41.4)	1 (7.6)	0.018
RRT ^b 1 (1) 0 (0) N/A Nitric oxide ^b 41 (43.6) 6 (46) 0.862 ECMO mode ^b 0.974 Veno-arterial 87 (92.5) 12 (92.3) 0.974 Veno-Venous 7 (7.5) 1 (7.6) 0.001 Cardiac 76 (80.8) 5 (38.4) 0.041 Central 57 (60.6) 4 (31) 0.041 Central 57 (60.6) 4 (31) 0.482 Outcomes and complications 0.041 0.041 0.041 Central 57 (60.6) 4 (31) 0.482 Outcomes and complications 0.041 0.041 0.0303 LOS (days) ^a 317 (90, 282) 130 (72, 163) 0.303 LOS (days) ^a 312 (21, 742) 364 (201, 566) 0.660 Complication (b) ^a 378 (216, 742) 364 (201, 566)	VAD ^b	9 (9.5)	0 (0)	N/A
Intric oxide ^b $(10,3)$ $(10,3)$ $(10,3)$ $(10,3)$ $(10,3)$ ECMO mode ^b ECMO data $(10,3)$ $(10,3)$ $(10,3)$ $(10,3)$ Veno-arterial 87 (92.5) 12 (92.3) $(10,3)$ $(11,3)$ <	RRT ^b	1 (1)	0 (0)	N/A
Inite Outle ECMO data 0.000 ECMO mode ^b 0.974 Veno-arterial 87 (92.5) 12 (92.3) Veno-Venous 7 (7.5) 1 (7.6) ECMO type ^b <0.001	Nitric oxide ^b	41 (43.6)	6 (46)	0.862
ECMO mode ^b 0.974 Veno-arterial 87 (92.5) 12 (92.3) Veno-Venous 7 (7.5) 1 (7.6) ECMO type ^b $<$ $<$ Cardiac 76 (80.8) 5 (38.4) Pulmonary 5 (5.3) 5 (38.4) ECPR 13 (13.9) 3 (23.2) Cannula location ^b 0.041 Central 57 (60.6) 4 (31) Peripheral 37 (39.4) 9 (69) Cardiac index ^a 1.97 (1.6, 2.5) 1.97 (1.5, 2.0) 0.482 Outcomes and complications 0000 0.482 ECMO duration (h) ^a 137 (90, 282) 130 (72, 163) 0.303 LOS (days) ^a 31 (21, 56) 38 (22, 53) 0.732 MV duration (h) ^a 378 (216, 742) 364 (201, 566) 0.660 Complication type ^b I I 0.00 N/A Eardiovascular 40 (42.5) 4 (31) 0.418 Hemorrhagic 39 (41.4) 4 (31) 0.459 Infectious 6 (6.3)		ECMO data	0 (10)	0.002
Veno-arterial $87 (92.5)$ $12 (92.3)$ Veno-Venous $7 (7.5)$ $1 (7.6)$ ECMO type ^b $< <<0.001$ Cardiac $76 (80.8)$ $5 (38.4)$ ECPR $13 (13.9)$ $3 (23.2)$ Cannula location ^b 0.041 Central $57 (60.6)$ $4 (31)$ Peripheral $37 (39.4)$ $9 (69)$ Cardiac index ^a $1.97 (1.6, 2.5)$ $1.97 (1.5, 2.0)$ 0.482 Outcomes and complications $000 (23.2)$ 0.303 ECMO duration (h) ^a $137 (90, 282)$ $130 (72, 163)$ 0.303 LOS (days) ^a $313 (21, 56)$ $38 (22, 53)$ 0.732 MV duration (h) ^a $137 (90, 282)$ $130 (72, 163)$ 0.303 LOS (days) ^a $318 (216, 742)$ $364 (201, 566)$ 0.660 Complication type ^b U U U 0.418 Hemorrhagic $39 (41.4)$ $4 (31)$ 0.418 Hemorrhagic $39 (41.4)$ $2 (15.4)$ 0.069 M detabolic $21 (22.3)$ $3 (23)$ 0.952 Neurologic $17 (18)$ $1 (7.6)$ 0.383 Renal $42 (44 6)$ $7 (53 8)$ 0.534	ECMO mode ^b			0.974
Veno-Venous7 (7.5)1 (7.6)ECMO type $<<<0.001Cardiac76 (80.8)5 (38.4)Pulmonary5 (5.3)5 (38.4)ECPR13 (13.9)3 (23.2)Cannula locationb0.041Central57 (60.6)4 (31)Peripheral37 (39.4)9 (69)Cardiac indexa1.97 (1.6, 2.5)1.97 (1.5, 2.0)Outcomes and complicationsECMO duration (h)a137 (90, 282)130 (72, 163)Outcomes and complicationsCardiovascular40 (42.5)4 (31)Outgradiantian0.418Hemorrhagic39 (41.4)4 (31)Infectious6 (6.3)1 (7.6)Uimb1 (1)0 (0)NYANYAStandard39 (41.4)2 (15.4)Outgoing17 (18)1 (7.6)Metabolic21 (22.3)3 (23)Operational30 (31)Cardiovascular40 (42.5)2 (15.4)Outgoing17 (18)1 (7.6)Outgoing31 (21, 56)Cardiovascular40 (42.5)Cardiovascular40 (42.5)Operational30 (41.4)Outgoing10 (0)NA7Respiratory25 (26.5)Cardio20 (15.4)Outgoing30 (23)OutgoingOutgoingCardiovascularCardiovascularCardiovascularCardiovascularOutgoingOutgoingOutgoingOu$	Veno-arterial	87 (92.5)	12 (92.3)	
ECMO type < < < < < < < < < <	Veno-Venous	7 (7.5)	1 (7.6)	
Cardiac 76 (80.8) 5 (38.4) Pulmonary 5 (5.3) 5 (38.4) ECPR 13 (13.9) 3 (23.2) Candia location ^b 0.041 Central 57 (60.6) 4 (31) Peripheral 37 (39.4) 9 (69) Cardiac index ^a 1.97 (1.6, 2.5) 1.97 (1.5, 2.0) 0.482 Outcomes and complications ECMO duration (h) ^a 137 (90, 282) 130 (72, 163) 0.303 LOS (days) ^a 31 (21, 56) 38 (22, 53) 0.732 MV duration (h) ^a 378 (216, 742) 364 (201, 566) 0.660 Complication type ^b 76 (6.3) 1 (7.6) 0.857 Limb 1 (1) 0 (0) N/A Mechanical 39 (41.4) 2 (15.4) 0.069 Metabolic 21 (22.3) 3 (23) 0.952 Neurologic 17 (18) 1 (7.6) 0.347 Respiratory 25 (26.5) 2 (15.4) 0.534	ECMO type ^b	. ()	- ()	<0.001
Pulmonary5 (5.3)5 (38.4)ECPR13 (13.9)3 (23.2)Cannula location ^b 0.041Central57 (60.6)4 (31)Peripheral37 (39.4)9 (69)Cardiac index ^a 1.97 (1.6, 2.5)1.97 (1.5, 2.0)Outcomes and complicationsECMO duration (h) ^a 137 (90, 282)130 (72, 163)Outcomes and complicationsECMO duration (h) ^a 378 (216, 742)364 (201, 566)0.660Complication type ^b Cardiovascular40 (42.5)4 (31)0.418Hemorrhagic39 (41.4)4 (31)0.459Infectious6 (6.3)1 (1)0 (0)N/AMechanical39 (41.4)2 (15.4)0.069Metabolic21 (22.3)3 (23)0.952Neurologic17 (18)1 (16)0.347Respiratory25 (26.5)2 (15.4)0.383	Cardiac	76 (80.8)	5 (38.4)	
ECR13 (13.9)3 (23.2)Cannula location ^b 0.041Central57 (60.6)4 (31)Peripheral37 (39.4)9 (69)Cardiac index ^a 1.97 (1.6, 2.5)1.97 (1.5, 2.0)0.482Outcomes and complicationsECMO duration (h) ^a 137 (90, 282)130 (72, 163)0.303LOS (days) ^a 31 (21, 56)38 (22, 53)0.732MV duration (h) ^a 378 (216, 742)364 (201, 566)0.660Cardiovascular40 (42.5)4 (31)0.418Hemorrhagic39 (41.4)4 (31)0.418Infectious6 (6.3)1 (7.6)0.857Limb1 (1)0 (0)N/AMechanical39 (41.4)2 (15.4)0.069Metabolic21 (22.3)3 (23)0.952Neurologic17 (18)1 (7.6)0.347Respiratory25 (26.5)2 (15.4)0.383Renal42 (44.6)7 (53.8)0.534	Pulmonary	5 (5.3)	5 (38.4)	
Cannula location ^b 0.041Central57 (60.6)4 (31)Peripheral37 (39.4)9 (69)Cardiac index ^a 1.97 (1.6, 2.5)1.97 (1.5, 2.0)0.482Outcomes and complicationsECMO duration (h) ^a 137 (90, 282)130 (72, 163)0.303LOS (days) ^a 31 (21, 56)38 (22, 53)0.732MV duration (h) ^a 378 (216, 742)364 (201, 566)0.660Complication type ^b Cardiovascular40 (42.5)4 (31)0.418Hemorrhagic39 (41.4)4 (31)0.418Infectious6 (6.3)1 (7.6)0.857Limb1 (1)0 (0)N/AMechanical39 (41.4)2 (15.4)0.069Metabolic21 (22.3)3 (23)0.952Neurologic17 (18)1 (7.6)0.347Respiratory25 (26.5)2 (15.4)0.383Real42 (44 6)7 (53.8)	ECPR	13 (13.9)	3 (23.2)	
Central57 (60.6)4 (31)Peripheral37 (39.4)9 (69)Cardiac index ^a 1.97 (1.6, 2.5)1.97 (1.5, 2.0)0.482Outcomes and complicationsECMO duration (h) ^a 137 (90, 282)130 (72, 163)0.303LOS (days) ^a 31 (21, 56)38 (22, 53)0.732MV duration (h) ^a 378 (216, 742)364 (201, 566)0.660Complication type ^b Cardiovascular40 (42.5)4 (31)0.418Hemorrhagic39 (41.4)4 (31)0.459Infectious6 (6.3)1 (7.6)0.857Limb1 (1)0 (0)N/AMechanical39 (41.4)2 (15.4)0.069Metabolic21 (22.3)3 (23)0.952Neurologic17 (18)1 (7.6)0.347Respiratory25 (26.5)2 (15.4)0.383Renal42 (44 6)7 (53.8)0.534	Cannula location ^b			0.041
Peripheral $37 (39.4)$ $9 (69)$ Cardiac index ^a $1.97 (1.6, 2.5)$ $1.97 (1.5, 2.0)$ 0.482 Outcomes and complicationsECMO duration (h) ^a $137 (90, 282)$ $130 (72, 163)$ 0.303 LOS (days) ^a $31 (21, 56)$ $38 (22, 53)$ 0.732 MV duration (h) ^a $378 (216, 742)$ $364 (201, 566)$ 0.660 Complication type ^b $40 (42.5)$ $4 (31)$ 0.418 Hemorrhagic $39 (41.4)$ $4 (31)$ 0.459 Infectious $6 (6.3)$ $1 (7.6)$ 0.857 Limb $1 (1)$ $0 (0)$ N/A Mechanical $39 (41.4)$ $2 (15.4)$ 0.069 Metabolic $21 (22.3)$ $3 (23)$ 0.952 Neurologic $17 (18)$ $1 (7.6)$ 0.347 Respiratory $25 (26.5)$ $2 (15.4)$ 0.383 Renal $42 (44 6)$ $7 (53.8)$ 0.534	Central	57 (60.6)	4 (31)	00011
Cardiac indexa1.97 (1.6, 2.5)1.97 (1.5, 2.0)0.482Outcomes and complicationsECMO duration (h)a137 (90, 282)130 (72, 163)0.303LOS (days)a31 (21, 56)38 (22, 53)0.732MV duration (h)a378 (216, 742)364 (201, 566)0.660Complication typebCardiovascular40 (42.5)4 (31)0.418Hemorrhagic39 (41.4)4 (31)0.459Infectious6 (6.3)1 (7.6)0.857Limb1 (1)0 (0)N/AMechanical39 (41.4)2 (15.4)0.069Metabolic21 (22.3)3 (23)0.952Neurologic17 (18)1 (7.6)0.347Respiratory25 (26.5)2 (15.4)0.383Renal42 (44 6)7 (53.8)0.534	Peripheral	37 (39.4)	9 (69)	
Intraction (International Content of the formation of the form	Cardiac index ^a	1.97 (1.6, 2.5)	1.97 (1.5, 2.0)	0.482
ECMO duration (h)a137 (90, 282)130 (72, 163)0.303LOS (days)a31 (21, 56)38 (22, 53)0.732MV duration (h)a378 (216, 742)364 (201, 566)0.660Complication typeb $(1, 2, 2, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3,$		Outcomes and complic	ations	01102
LOS (days) ^a 10 (21, 56)38 (22, 53)0.732LOS (days) ^a 31 (21, 56)38 (22, 53)0.732MV duration (h) ^a 378 (216, 742)364 (201, 566)0.660Complication type ^b $(1, 2, 5)$ 4 (31)0.418Cardiovascular40 (42.5)4 (31)0.459Infectious6 (6.3)1 (7.6)0.857Limb1 (1)0 (0)N/AMechanical39 (41.4)2 (15.4)0.069Metabolic21 (22.3)3 (23)0.952Neurologic17 (18)1 (7.6)0.347Respiratory25 (26.5)2 (15.4)0.383Renal42 (44 6)7 (53.8)0.534	ECMO duration (h) ^a	137 (90, 282)	130 (72, 163)	0.303
DiscreteDiscreteDiscreteDiscreteDiscreteDiscreteDiscreteMV duration (h)a $378 (216, 742)$ $364 (201, 566)$ 0.660 Complication type ^b $40 (42.5)$ $4 (31)$ 0.418 Cardiovascular $40 (42.5)$ $4 (31)$ 0.459 Infectious $6 (6.3)$ $1 (7.6)$ 0.857 Limb $1 (1)$ $0 (0)$ N/AMechanical $39 (41.4)$ $2 (15.4)$ 0.069 Metabolic $21 (22.3)$ $3 (23)$ 0.952 Neurologic $17 (18)$ $1 (7.6)$ 0.347 Respiratory $25 (26.5)$ $2 (15.4)$ 0.383 Renal $42 (44 6)$ $7 (53 8)$ $0 534$	LOS (days) ^a	31 (21, 56)	38 (22, 53)	0.732
Complication type ^b 617 (213, 712) 617 (213, 703) 618 (213, 703) Cardiovascular 40 (42.5) 4 (31) 0.418 Hemorrhagic 39 (41.4) 4 (31) 0.459 Infectious 6 (6.3) 1 (7.6) 0.857 Limb 1 (1) 0 (0) N/A Mechanical 39 (41.4) 2 (15.4) 0.069 Metabolic 21 (22.3) 3 (23) 0.952 Neurologic 17 (18) 1 (7.6) 0.347 Respiratory 25 (26.5) 2 (15.4) 0.383 Renal 42 (44 6) 7 (53 8) 0 534	MV duration (h) ^a	378 (216, 742)	364 (201, 566)	0.660
Cardiovascular 40 (42.5) 4 (31) 0.418 Hemorrhagic 39 (41.4) 4 (31) 0.459 Infectious 6 (6.3) 1 (7.6) 0.857 Limb 1 (1) 0 (0) N/A Mechanical 39 (41.4) 2 (15.4) 0.069 Metabolic 21 (22.3) 3 (23) 0.952 Neurologic 17 (18) 1 (7.6) 0.347 Respiratory 25 (26.5) 2 (15.4) 0.383 Renal 42 (44 6) 7 (53 8) 0 534	Complication type ^b			0.000
Hemorrhagic 39 (41.4) 4 (31) 0.459 Infectious 6 (6.3) 1 (7.6) 0.857 Limb 1 (1) 0 (0) N/A Mechanical 39 (41.4) 2 (15.4) 0.069 Metabolic 21 (22.3) 3 (23) 0.952 Neurologic 17 (18) 1 (7.6) 0.347 Respiratory 25 (26.5) 2 (15.4) 0.383 Renal 42 (44 6) 7 (53 8) 0 534	Cardiovascular	40 (42.5)	4 (31)	0.418
Infectious 6 (6.3) 1 (7.6) 0.857 Limb 1 (1) 0 (0) N/A Mechanical 39 (41.4) 2 (15.4) 0.069 Metabolic 21 (22.3) 3 (23) 0.952 Neurologic 17 (18) 1 (7.6) 0.347 Respiratory 25 (26.5) 2 (15.4) 0.383 Renal 42 (44.6) 7 (53.8) 0.534	Hemorrhagic	39 (41.4)	4 (31)	0.459
Limb 1 (1) 0 (0) N/A Mechanical 39 (41.4) 2 (15.4) 0.069 Metabolic 21 (22.3) 3 (23) 0.952 Neurologic 17 (18) 1 (7.6) 0.347 Respiratory 25 (26.5) 2 (15.4) 0.383 Renal 42 (44.6) 7 (53.8) 0.534	Infectious	6 (6 3)	1 (7 6)	0.857
Mechanical 39 (41.4) 2 (15.4) 0.069 Metabolic 21 (22.3) 3 (23) 0.952 Neurologic 17 (18) 1 (7.6) 0.347 Respiratory 25 (26.5) 2 (15.4) 0.383 Renal 42 (44.6) 7 (53.8) 0.534	Limb	1 (1)	0 (0)	N/A
Metabolic 21 (22.3) 3 (23) 0.952 Neurologic 17 (18) 1 (7.6) 0.347 Respiratory 25 (26.5) 2 (15.4) 0.383 Renal 42 (44.6) 7 (53.8) 0.534	Mechanical	39(414)	2(154)	0.060
Neurologic 17 (18) 1 (7.6) 0.347 Respiratory 25 (26.5) 2 (15.4) 0.383 Renal 42 (44.6) 7 (53.8) 0.534	Metabolic	21 (22 3)	3 (23)	0.009
Respiratory 25 (26.5) 2 (15.4) 0.383 Renal 42 (44.6) 7 (53.8) 0.534	Neurologic	17 (18)	1 (7 6)	0.552
Respinety $25(20.5)$ $2(15.4)$ 0.585 Renal $42.(44.6)$ $7(53.8)$ 0.534	Respiratory	25 (26 5)	2(154)	0.347
	Renal	42 (44.6)	7 (53.8)	0.535

^a Medians (IQR).
^b Frequencies (%).
BP: blood pressure, BSA: body surface area, CHD: congenital heart disease, CPB: cardiopulmonary bypass, ECMO: extracorporeal membrane oxygenation, ECPR: extracorporeal cardiopulmonary resuscitation, FiO2: fraction of inspired oxygen, HFOV: high-frequency oscillatory ventilation, h: hours, LOS: length of stay, MV: mechanical ventilation, RRT: renal replacement therapy, VAD: ventricular assist device. Heart failure includes cardiomyopathy, myocarditis, and heart transplant.

Table 3. Fully adjusted multivariable logistic regression to ascertain factors associated with survival to hospital discharge.

Predictor	OR (95% CI)	<i>p</i> -value
LOS (days)	1.03 (1.01, 1.04)	<0.001
Ventilator type (HFOV vs Conventional)	28.44 (3.52, 229.58)	< 0.001
Ventilator type (Other vs Conventional)	0.08 (0, 1.5)	<0.001
Absence of hemorrhagic complication	3.51 (1.12, 11.05)	0.031
Absence of renal complication	3.50 (1.15, 10.63)	0.027

CI: confidence interval, HFOV: High-frequency oscillatory ventilation, LOS: length of stay, OR: odds ratio.

The primary strength of this study is that it represents the largest and first report of pediatric cardiac patients with PH on ECMO including international multicenter data. Nonetheless, we acknowledge several limitations. It is a retrospective database review that depends on accurate data reporting from multiple ECMO centers worldwide. Center variation in the use of ECMO could not be accounted for. Additionally, while a statistically significant survival benefit was identified with the utilization of HFOV before ECMO cannulation in these patients, the power of this association is limited by the small number of patients who utilized HFOV compared to other ventilatory strategies. Furthermore, underlying differences in disease characteristics between patients on conventional modes vs HFOV, which are not fully captured in the ELSO registry, may have also contributed to these findings. Finally, we were not able to adjust for unreported factors associated with worse outcomes such as severity of illness scores, congenital heart surgery procedural scores, and unrecorded comorbidities.

In conclusion, in pediatric cardiac patients with acute pulmonary hemorrhage, the use of HFOV before ECMO cannulation is independently associated with improved survival. A prospective evaluation of mechanical ventilation practices preceding ECMO may enhance outcomes in this medically complex population.

Acknowledgements

The authors thank Meredith Ray, PhD from the Division of Epidemiology, Biostatistics, and Environmental Health at the University of Memphis, for the statistical support.

Funding

This research did not receive any specific funding.

Conflicts of interest

Authors declared no conflict of interest.

Data availability statement

The data are available from the corresponding author on request (with permission from the ELSO).

Author contribution statement

P.A.M., H.S. designed this study. P.A.M. performed the research and analyzed the data. P.A.M., C.Y., S.V. wrote the manuscript, and all authors contributed to the final version.

Ethics approval

We utilized the Extracorporeal Life Support Organization (ELSO) registry database for this retrospective study. The Institutional Review Board at the University of Tennessee Health Science Center reviewed the study and determined it to be Not Human Subjects Research status (IRB No. 22-08818-NHSR).

References

- Godfrey S. Pulmonary hemorrhage/hemoptysis in children. Pediatr Pulmonol. 2004;37:476–484.
- Coss-Bu JA, Sachdeva RC, Bricker JT, Harrison GM, Jefferson LS. Hemoptysis: a 10-year retrospective study. Pediatrics. 1997;100:E7.
- Baroutidou A, Arvanitaki A, Hatzidakis A, et al. Haemoptysis in pulmonary arterial hypertension associated with congenital heart disease: insights on pathophysiology, diagnosis and management. J Clin Med. 2022;11:633.
- 4. Knoflach K, Rapp CK, Schwerk N, et al. Diffuse alveolar hemorrhage in children with interstitial lung disease: determine etiologies!. Pediatr Pulmonol. 2023;58:1106–1121.
- Martìnez-Martìnez MU, Abud-Mendoza C. Diffuse alveolar hemorrhage in patients with systemic lupus erythematosus. Clinical manifestations, treatment, and prognosis. Reumatol Clin. 2014;10:248–253.
- Pappas MD, Sarnaik AP, Meert KL, Hasan RA, Lieh-Lai MW. Idiopathic pulmonary hemorrhage in infancy. Clinical features and management with high frequency ventilation. Chest. 1996;110:553–555.
- Delvino P, Monti S, Balduzzi S, Belliato M, Montecucco C, Caporali R. The role of extra-corporeal membrane oxygenation (ECMO) in the treatment of diffuse alveolar haemorrhage secondary to ANCA-associated vasculitis: report of two cases and review of the literature. Rheumatol Int. 2019;39:367–375.
- Udi J, Köhler TC, Grohmann J, et al. A challenging case of severe pulmonary bleeding in a patient with congenital ventricular septal defect (VSD) and Eisenmenger syndrome: extracorporeal membrane oxygenation (ECMO) support and weaning strategies. Clin Res Cardiol. 2020;109:403–407.
- Kimura D, Shah S, Briceno-Medina M, et al. Management of massive diffuse alveolar hemorrhage in a child with systemic lupus erythematosus. J Intensive Care. 2015;3:10.
- Chakraborty A, Beasley G, Martinez H, et al. Selumetinib for refractory pulmonary and gastrointestinal bleeding in noonan syndrome. Pediatrics. 2022;150:e2022056336.
- Pacheco Claudio C, Charbonney E, Durand M, Kolan C, Laskine M. Extracorporeal membrane oxygenation in diffuse alveolar hemorrhage secondary to systemic lupus erythematosus. J Clin Med Res. 2014;6:145–148.
- Ahmed SH, Aziz T, Cochran J, Highland K. Use of extracorporeal membrane oxygenation in a patient with diffuse alveolar hemorrhage. Chest. 2004;126:305–309.
- Kolovos NS, Schuerer DJ, Moler FW, et al. Extracorporeal life support for pulmonary hemorrhage in children: a case series. Crit Care Med. 2002;30:577–580.

- 14. de Jager P, Curley MAQ, Cheifetz IM, Kneyber MCJ. Hemodynamic effects of a high-frequency oscillatory ventilation open-lung strategy in critically ill children with acquired or congenital cardiac disease. Pediatr Crit Care Med. 2023;24: e272–e281.
- 15. Aubron C, Cheng AC, Pilcher D, et al. Factors associated with outcomes of patients on extracorporeal membrane oxygenation support: a 5-year cohort study. Crit Care. 2013; 17:R73.
- 16. Strong AE, Zee J, Fulchiero R, et al. Intravascular hemolysis and AKI in children undergoing extracorporeal membrane oxygenation. Kidney360. 2023;4:1536–1544.
- 17. Alimi A, Taytard J, Abou Taam R, et al. Pulmonary hemosiderosis in children with down syndrome: a national experience. Orphanet J Rare Dis. 2018;13:60.
- Bloom JL, Frank B, Weinman JP, et al. Diffuse alveolar hemorrhage in children with trisomy 21. Pediatr Rheumatol Online J. 2021;19:114.
- Raj SS, Slaven JE, Rigby MR. Factors associated with survival during high-frequency oscillatory ventilation in children. J Pediatr Intensive Care. 2015;4:146–155.
- Bojan M, Gioanni S, Mauriat P, Pouard P. High-frequency oscillatory ventilation and short-term outcome in neonates and infants undergoing cardiac surgery: a propensity score analysis. Crit Care. 2011;15:R259.

Cite this article as: Anton-Martin P, Young C, Sandhu H & Vellore S. Pediatric cardiac patients with pulmonary hemorrhage supported on ECMO: An ELSO registry study. J Extra Corpor Technol 2025, **57**, 2–8. https://doi.org/10.1051/ject/2024038.